MDS Analytical Technologies Releases MetaXpressPowerCore(TM) and MetaXpress(R) 3.0 Cellular Imaging Software
27 April 2009 - 8:00AM
PR Newswire (US)
Enhancements Increase Flexibility and High-Content Screening
Throughput SUNNYVALE, CA, April 27 /PRNewswire-FirstCall/ -- MDS
Analytical Technologies, a leader in innovative solutions for drug
discovery and life sciences research, today announced at the
Society for Biomolecular Sciences (SBS) Conference and Exhibition
2009 in Lille, France, the availability of the
MetaXpressPowerCore(TM) and MetaXpress(R) 3.0 image acquisition and
analysis software. These advancements are designed to accelerate
the throughput of High-Content Screening (HCS) and expand toxicity
applications to include micronuclei detection.
MetaXpressPowerCore(TM) software improves workflow and
significantly reduces overall time required for HCS screens by
dramatically increasing image analysis speeds. Image analysis is
improved by leveraging a novel parallel-processing infrastructure
that can be scaled to the user's throughput need.
MetaXpressPowerCore(TM) software integrates with the existing
MetaXpress(R) platform and MDCStore(TM) data-management solution,
and is licensed by the number of processes required.
MetaXpressPowerCore(TM) is compatible with the entire suite of
MetaXpress(R) application modules. MetaXpress(R) 3.0 software
introduces a number of ease-of-use improvements, including new
data- management utilities, such as database optimization, data
archival and deletion. MetaXpress(R) 3.0 analysis is compatible
with Microsoft's Windows Vista operating system, and runs all of
the most recent features of MetaMorph(R) 7.6 software. "Cellular
imaging technology has become integral to drug discovery, research
and screening, and improvements in flexibility and speed are
critical for customers," said Andy Boorn, President of MDS
Analytical Technologies. "The next milestone for HCS is scaling up
to primary screening with imaging technology. Elimination of image
analysis bottlenecks with these new products is a major
accomplishment toward realizing this goal." Another enhancement to
MetaXpress(R) 3.0 software is the release of the Micronuclei
Application Module that allows users to find, evaluate and
quantitate micronuclei in nucleated cells for HCS. This product
uses a proprietary algorithm that is a significant improvement over
existing competitive micronuclei detection methods. Using
additional probes, this new application module makes it possible
for users to additionally differentiate between mitotic, apoptotic,
and necrotic cells, expanding the toxicology measurement suite
significantly. MDS Analytical Technologies at SBS Conference and
Exhibition 2009 MetaXpressPowerCore(TM) and MetaXpress(R) 3.0
software programs are being presented to attendees at the Society
for Biomolecular Sciences Conference and Exhibition 2009, which is
being held April 26-30, in Lille, France. MDS Analytical
Technologies can be found at booth 76. About MetaXpress(R) Software
The MetaXpress(R) program is based on the MetaMorph(R) software
backbone, and is used to power the suite of cellular imaging
instruments and analysis software for automated imaging and HCS.
MetaXpress(R) software is integrated with a data-management
solution, turnkey application modules, and the PowerCore analysis
option that increases the flexibility and overall speed of
workflow. About MDS Analytical Technologies MDS Analytical
Technologies, a business unit of MDS Inc., is focused on the
research, design, manufacture and marketing of state-of-the-art
tools for mass-spectrometry, drug discovery and bioresearch. MDS
Analytical Technologies' products are designed to help accelerate
the complex process of discovering and developing new drug
compounds, and are sold to research scientists around the world.
The mass-spectrometer product lines are also sold globally through
joint ventures with two of the world's leading analytical
instrumentation and life-sciences companies, Life Technologies
Corporation and PerkinElmer, Inc. Find out more at
http://www.mdssciex.com/ or http://www.moleculardevices.com/. About
MDS Inc. MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life-sciences
company that provides market-leading products and services that our
customers need for the development of drugs and diagnosis and
treatment of disease. We are a leading global provider of
pharmaceutical contract research, medical isotopes for molecular
imaging, radiotherapeutics, and analytical instruments. MDS, Inc.
has more than 5,000 highly skilled people in 29 countries. Find out
more at http://www.mdsinc.com/ or by calling 1-888-MDS-7222, 24
hours a day. DATASOURCE: MDS Inc. CONTACT: MEDIA: Tom Driscoll,
(408) 747-3681, ; INVESTORS: Kim Lee, (416) 213-4721,
Copyright